The primary endpoint for the SPARTAN, PROSPER, and ARAMIS trials was metastasis-free survival. SPARTAN randomly assigned 1207 patients with nmCRPC 2:1 to receive the next generation AR antagonist apalutamide vs placebo. PROSPER randomly assigned 1401 patients with nmCRPC 2:1 to receive enzalutamide vs placebo. ARAMIS randomly assigned 1509 patients with nmCRPC 2:1 to receive darolutamide vs placebo. Metastasis-free survival was significantly better in all three trials when the trial drug was compared with placebo, with hazard ratios of 0.28, 0.29, and 0.41, respectively.
Although overall survival is an important measure of drug efficacy, this endpoint takes time to mature.
Overall response rate and progression-free survival are traditional surrogate endpoints that may be poor correlates for overall survival in certain novel therapies.
Learn more about the SPARTAN, PROSPER and ARAMIS trials.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Kyle A. Richards. Fast Five Quiz: Castration-Resistant Prostate Cancer - Medscape - Dec 02, 2020.